Oncology Advancing radiopharmaceutical development: Preclinical preci... Radiopharmaceutical development must move beyond fixed paradigms toward patient-specific, data-driven optimisation.
News Radiopharma CDMO Nucleus names former FDA boss as CEO CDMO Nucleus RadioPharma has a high-profile new CEO: former FDA Commissioner and veteran cancer researcher Dr Stephen Hahn.
News New radiopharma Actithera emerges with $75.5m in financing A new player in radioligand therapies, Actithera, has arrived on the scene with $75.5m in funding and lead FAP-targeted candidate for cancer.
News BMS' radiopharma unit builds with $1.35bn Philochem deal Bristol Myers Squibb has expanded its push into radiopharma by licensing a prostate cancer therapy developed by Philochem for $350m upfront.
R&D The growth of radiotherapeutics: Addressing supply chain com... Players, current and emergent, should prepare for complexities in the supply chain as radiotherapeutics continues to rise.
News Healthineers offers €200m for Novartis radiodiagnostics unit Siemens Healthineers has agreed a €200 million ($224 million) deal to buy the diagnostic arm of Novartis' Advanced Accelerator Applications (AAA) radiopharma unit, boosting its medical imag
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
